Tumors of female reproductive systemTumors of female reproductive systemОпухоли женской репродуктивной системы1994-40981999-8627Publishing House ABV Press20310.17650/1994-4098-2011-0-4-76-83GYNECOLOGY. DIAGNOSISГИНЕКОЛОГИЯ. ДИАГНОСТИКАIdentification of proteomic markers for metastasis of ovarian cancerИдентификация протеомных маркеров метастазирования рака яичниковShevchenkoV. E.ШевченкоВ. Е.
Russian Federation
vshev@nm.ruMakarovD. E.МакаровД. Е.KovalevS. V.КовалевС. В.ArnotskayaN. E.АрноцкаяН. Е.PogosyanN. R.ПогосянН. Р.ZhordaniaK. I.ЖорданиаК. И.Oncoproteomics Laboratory N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, MoscowЛаборатория онкопротеомики ФГБУ РОНЦ им. Н.Н. Блохина РАМН, МоскваGynecology Department N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, MoscowГинекологическое отделение ФГБУ РОНЦ им. Н.Н. Блохина РАМН, Москва181120114768321082014210820142011https://ojrs.abvpress.ru/ojrs/article/view/203

The proteome of ascites and pleural fluids (AF and PF) was mapped in patients with ovarian cancer (OC). 240 and 190 proteins were identi- fied with a high degree of assurance in A F and PF, respectively . The major portion w as extracellular and membrane proteins, whi ch ac- counted for 45 and 49 % in AF and PF, respectively. Analysis of the proteomic maps of AF and PF indicated that 82 proteins were common to these biological fluids whereas 81 and 49 proteins were unique to A F and PF, respectively. A list of 46 potential markers for O C metastasis and potential markers for tropic OC metastasis over the peritoneal (17 proteins) and pleural (11 proteins) surfaces is given.

Проведено картирование протеома асцитной (АЖ) и плевральной (ПЖ) жидкостей больных раком яичников (РЯ). В результате в АЖ с высокой степенью достоверности были идентифицированы 240, а в ПЖ — 190 белков. Значительную часть составляли внеклеточные и мембранные белки, на долю которых приходилось 45 и 49 % для АЖ и ПЖ соответственно. Анализ протеомных карт АЖ и ПЖ показал, что 82 белка для этих биологических жидкостей являются общими, тогда как 81 — уникален для АЖи 49 — для ПЖ. Представлен список из 46 потенциальных маркеров метастазирования РЯ и потенциальных маркеров тропного метастазирования РЯ по перитонеальной (17 белков) и плевральной (11 белков) поверхностям.

ovarian cancerascites fluidpleural fluidproteomicsmass spectrometrybiomarkers of metastasisрак яичниковасцитная жидкостьплевральная жидкостьпротеомикамасс-спектрометриямаркеры метастазирования1. Lu X., Kang Y. Discovery of bone metastasis genes by functional genomics. PharmDD 2005;5:32–5.Lu X., Kang Y. Discovery of bone metastasis genes by functional genomics. PharmDD 2005;5:32–5.2. Jemal A., Murray T.,Ward E. et al. Cancer statistics 2005. CA Cancer J Clin 2005;55:10–30.Jemal A., Murray T.,Ward E. et al. Cancer statistics 2005. CA Cancer J Clin 2005;55:10–30.3. Шевченко В.Е., Арноцкая Н.Е., Макаров Д.Е. и др. Протеомика в диагностике рака яичников. ОЖРС 2011;2:56–64.Шевченко В.Е., Арноцкая Н.Е., Макаров Д.Е. и др. Протеомика в диагностике рака яичников. ОЖРС 2011;2:56–64.4. Curtin J.P., Malik R., Venkatraman E.S. et al. Stage IV ovarian cancer: impact of surgical debulking. Gynecol Oncol 1997;64:9–12.Curtin J.P., Malik R., Venkatraman E.S. et al. Stage IV ovarian cancer: impact of surgical debulking. Gynecol Oncol 1997;64:9–12.5. Bonnefoi H., A’Hern R.P., Fisher C. et al. Natural history of stage IV epithelial ovarian cancer. J Clin Oncol 1999;17:767–75.Bonnefoi H., A’Hern R.P., Fisher C. et al. Natural history of stage IV epithelial ovarian cancer. J Clin Oncol 1999;17:767–75.6. Griffiths C.T., Parker L.M., Fuller A. Jr. Role of cytoreductive surgical treatment in the management of advanced ovarian cancer. Cancer Treat Rep 1979;63:235–40.Griffiths C.T., Parker L.M., Fuller A. Jr. Role of cytoreductive surgical treatment in the management of advanced ovarian cancer. Cancer Treat Rep 1979;63:235–40.7. Zebrowski B.K., Yano S., Liu W. et al. Vascular endothelial growth factor levels and induction of permeability in malignant pleural effusions. Clin Cancer Res 1999;5:3364–8.Zebrowski B.K., Yano S., Liu W. et al. Vascular endothelial growth factor levels and induction of permeability in malignant pleural effusions. Clin Cancer Res 1999;5:3364–8.8. Feldman G.B., Knapp R.C., Order S.E. et al. The role of lymphatic obstruction in the formation of ascites in a murine ovarian carcinoma. Cancer Res 1972;32:1663–6.Feldman G.B., Knapp R.C., Order S.E. et al. The role of lymphatic obstruction in the formation of ascites in a murine ovarian carcinoma. Cancer Res 1972;32:1663–6.9. AbramovY., Anteby S.O., Fasouliotis S.J. et al. The role of inflammatory cytokines in Meigs’ syndrome. Obstet Gynecol 2002; 99:917–9.AbramovY., Anteby S.O., Fasouliotis S.J. et al. The role of inflammatory cytokines in Meigs’ syndrome. Obstet Gynecol 2002; 99:917–9.10. Davidson B., Reich R., Kopolovic J. et al. Interleukin-8 and vascular endothelial growth factor mRNA and proteinlevels are down- regulatedinovarian carcinoma cells in serous effusions. Clin Exp Metastas 2002;19:135–44.Davidson B., Reich R., Kopolovic J. et al. Interleukin-8 and vascular endothelial growth factor mRNA and proteinlevels are down- regulatedinovarian carcinoma cells in serous effusions. Clin Exp Metastas 2002;19:135–44.11. Fang X., Yu S., Bast R.C. et al. Mechanisms for lysophosphatidic acid-induced cytokine production in ovarian cancer cells. J Biol Chem 2004;279:9653–61.Fang X., Yu S., Bast R.C. et al. Mechanisms for lysophosphatidic acid-induced cytokine production in ovarian cancer cells. J Biol Chem 2004;279:9653–61.12. Bedrossian C.W. Diagnostic problems in serous effusions. Diagn Cytopathol 1998; 19:131–7.Bedrossian C.W. Diagnostic problems in serous effusions. Diagn Cytopathol 1998; 19:131–7.13. Liotta L.A., Kohn E.C. The microenvironment of the tumour-host interface. Nature 2001;411:375–9.Liotta L.A., Kohn E.C. The microenvironment of the tumour-host interface. Nature 2001;411:375–9.14. Hu L., Hofmann J., Zaloudek C. et al. Vascular endo thelial growth factor immunoneutralization plus Paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer. Am J Pathol 2002;161(5):1917–24.Hu L., Hofmann J., Zaloudek C. et al. Vascular endo thelial growth factor immunoneutralization plus Paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer. Am J Pathol 2002;161(5):1917–24.15. Berchuck A., Carney M. Human ovarian cancer of the surface epithelium. Biochem Pharmacol 1997;54(5):541–4.Berchuck A., Carney M. Human ovarian cancer of the surface epithelium. Biochem Pharmacol 1997;54(5):541–4.16. Gortzak-Uzan L., Ignatchenko A., Evangelou A.I. et al. A proteome resource of ovarian cancer ascites: integrated proteomic and bioinformatic analyses to identify putative biomarkers. J Proteome Res 2008;7:339–51.Gortzak-Uzan L., Ignatchenko A., Evangelou A.I. et al. A proteome resource of ovarian cancer ascites: integrated proteomic and bioinformatic analyses to identify putative biomarkers. J Proteome Res 2008;7:339–51.17. Шевченко В.Е. Современные масс- спектрометрические методы в ранней диагностике рака. Масс-спектрометрия 2004;1(2):103–26.Шевченко В.Е. Современные масс- спектрометрические методы в ранней диагностике рака. Масс-спектрометрия 2004;1(2):103–26.18. Шевченко В.Е., Арноцкая Н.Е., Трифонова О.П. и др. Профилирование низкомолекулярного протеома плазмы крови для обнаружения потенциальных маркеров рака легкого. Масс-спектро- метрия 2007;4(4):245–54.Шевченко В.Е., Арноцкая Н.Е., Трифонова О.П. и др. Профилирование низкомолекулярного протеома плазмы крови для обнаружения потенциальных маркеров рака легкого. Масс-спектро- метрия 2007;4(4):245–54.19. Пятницкий М.А., Лисица А.В., Шевченко В.Е. и др. Выявление дифференциальных признаков плоскоклеточного рака легкого с помощью масс- спектрометрического профилирования плазмы крови. Масс-спектрометрия 2011; 8(2):99–105.Пятницкий М.А., Лисица А.В., Шевченко В.Е. и др. Выявление дифференциальных признаков плоскоклеточного рака легкого с помощью масс- спектрометрического профилирования плазмы крови. Масс-спектрометрия 2011; 8(2):99–105.20. Cho C.K., Shan S.J., Winsor E.J. et al. Proteomic analysis of human amniotic fluid. Mol Cell Proteom 2007;6:1406–15.Cho C.K., Shan S.J., Winsor E.J. et al. Proteomic analysis of human amniotic fluid. Mol Cell Proteom 2007;6:1406–15.21. Shaw J.L., Smith C.R., Diamandis E.P. Proteomic analysis of human cervico-vaginal fluid. J Proteome Res 2007;6:2859–65.Shaw J.L., Smith C.R., Diamandis E.P. Proteomic analysis of human cervico-vaginal fluid. J Proteome Res 2007;6:2859–65.22. Shevchenko V.E., Arnotskaya N.E., Zaridze D.G. Detection of lung cancer using plasma protein profiling by matrix-assisted laser desorption/ionization mass spectrometry. Eur J Mass Spectrom 2010;16(4):539–49.Shevchenko V.E., Arnotskaya N.E., Zaridze D.G. Detection of lung cancer using plasma protein profiling by matrix-assisted laser desorption/ionization mass spectrometry. Eur J Mass Spectrom 2010;16(4):539–49.23. Pilch B., Mann M. Large-scale and high- confidence proteomic analysis of human seminal plasma. Genome Biol 2006;7:40.Pilch B., Mann M. Large-scale and high- confidence proteomic analysis of human seminal plasma. Genome Biol 2006;7:40.24. Gunawardana C.G., Kuk C., Smith C.R. et al. Comprehensive analysis of conditioned media from ovarian cancer cell lines identifies novel candidate markers of epithelial ovarian cancer. J. Proteom Res 2009;8:4705–13.Gunawardana C.G., Kuk C., Smith C.R. et al. Comprehensive analysis of conditioned media from ovarian cancer cell lines identifies novel candidate markers of epithelial ovarian cancer. J. Proteom Res 2009;8:4705–13.25. Hu L., Hofmann J., Zaloudek C. et al. Vascular endothelial growth factor immunoneutralization plus Paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer. Am J Pathol 2002;161(5):1917–24.Hu L., Hofmann J., Zaloudek C. et al. Vascular endothelial growth factor immunoneutralization plus Paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer. Am J Pathol 2002;161(5):1917–24.26. Шевченко В.Е., Ковалев С.В., Юрченко В.А. и др. Картирование протеома плазмы крови человека в норме и при светлоклеточном раке почки. Онкоурология 2011;3:65–9.Шевченко В.Е., Ковалев С.В., Юрченко В.А. и др. Картирование протеома плазмы крови человека в норме и при светлоклеточном раке почки. Онкоурология 2011;3:65–9.27. Williams T.I., Toups K.L., Saggese D.A. et al. Epithelial ovarian cancer: disease etiology, treatment, detection, and investigational gene, metabolite, and protein biomarkers. J Proteom Res 2007; 6:2936–62.Williams T.I., Toups K.L., Saggese D.A. et al. Epithelial ovarian cancer: disease etiology, treatment, detection, and investigational gene, metabolite, and protein biomarkers. J Proteom Res 2007; 6:2936–62.